Psybio Therapeutics Corp Stock Buy Hold or Sell Recommendation
| PSYBF Stock | USD 0.0001 0.00 0.00% |
Assuming the 90 days horizon and your above-average risk tolerance, our recommendation regarding PsyBio Therapeutics Corp is 'Strong Sell'. Macroaxis provides PsyBio Therapeutics buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding PSYBF positions.
Check out PsyBio Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note, we conduct extensive research on individual companies such as PsyBio and provide practical buy, sell, or hold advice based on investors' constraints. PsyBio Therapeutics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.
PsyBio |
Execute PsyBio Therapeutics Buy or Sell Advice
The PsyBio recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on PsyBio Therapeutics Corp. Macroaxis does not own or have any residual interests in PsyBio Therapeutics Corp or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute PsyBio Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Out of control | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Moves totally opposite to the market | Details | |
Analyst Consensus | Not Available | Details | |
Reporting Quality (M-Score) | Inapplicable | Details |
PsyBio Therapeutics Trading Alerts and Improvement Suggestions
| PsyBio Therapeutics generated a negative expected return over the last 90 days | |
| PsyBio Therapeutics has high historical volatility and very poor performance | |
| PsyBio Therapeutics has some characteristics of a very speculative penny stock | |
| PsyBio Therapeutics Corp has accumulated 207.81 K in total debt with debt to equity ratio (D/E) of 7.03, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. PsyBio Therapeutics Corp has a current ratio of 0.87, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist PsyBio Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, PsyBio Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like PsyBio Therapeutics Corp sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for PsyBio to invest in growth at high rates of return. When we think about PsyBio Therapeutics' use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (11.02 M) with loss before overhead, payroll, taxes, and interest of (1.56 M). | |
| PsyBio Therapeutics Corp has accumulated about 911.83 K in cash with (6.95 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 26.0% of PsyBio Therapeutics outstanding shares are owned by corporate insiders |
PsyBio Therapeutics Returns Distribution Density
The distribution of PsyBio Therapeutics' historical returns is an attempt to chart the uncertainty of PsyBio Therapeutics' future price movements. The chart of the probability distribution of PsyBio Therapeutics daily returns describes the distribution of returns around its average expected value. We use PsyBio Therapeutics Corp price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of PsyBio Therapeutics returns is essential to provide solid investment advice for PsyBio Therapeutics.
| Mean Return | -1.48 | Value At Risk | 0.00 | Potential Upside | 0.00 | Standard Deviation | 12.06 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of PsyBio Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
PsyBio Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to PsyBio Therapeutics or Healthcare sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that PsyBio Therapeutics' price will be affected by overall pink sheet market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a PsyBio pink sheet's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -1.4 | |
β | Beta against Dow Jones | -1.07 | |
σ | Overall volatility | 12.65 | |
Ir | Information ratio | -0.13 |
PsyBio Therapeutics Volatility Alert
PsyBio Therapeutics Corp is displaying above-average volatility over the selected time horizon. PsyBio Therapeutics Corp appears to be a penny stock. Although PsyBio Therapeutics Corp may be, in fact, a solid short-term or long term investment, many penny pink sheets are speculative investment instruments that are often subject to artificial stock promotion and campaigns of hype which may lead to misinformation and misrepresentation. Please make sure you fully understand upside potential and downside risks of investing in PsyBio Therapeutics Corp or similar risky assets. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswing without any event/news,and sudden news releases. We also encourage traders to check biographies and work history of company President, CEO or other officers before investing in high-volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on PsyBio instrument if you perfectly time your entry and exit. However, remember that penny pink sheets that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.PsyBio Therapeutics Fundamentals Vs Peers
Comparing PsyBio Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze PsyBio Therapeutics' direct or indirect competition across all of the common fundamentals between PsyBio Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as PsyBio Therapeutics or determine the pink sheets which would be an excellent addition to an existing portfolio. Peer analysis of PsyBio Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing PsyBio Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare PsyBio Therapeutics to competition |
| Fundamentals | PsyBio Therapeutics | Peer Average |
| Return On Equity | -3.1 | -0.31 |
| Return On Asset | -0.98 | -0.14 |
| Current Valuation | 3.69 M | 16.62 B |
| Shares Outstanding | 80.85 M | 571.82 M |
| Shares Owned By Insiders | 25.61 % | 10.09 % |
| Shares Owned By Institutions | 13.23 % | 39.21 % |
| Price To Book | 202.42 X | 9.51 X |
| Gross Profit | (1.56 M) | 27.38 B |
| EBITDA | (10.91 M) | 3.9 B |
| Net Income | (11.02 M) | 570.98 M |
| Cash And Equivalents | 911.83 K | 2.7 B |
| Cash Per Share | 0.01 X | 5.01 X |
| Total Debt | 207.81 K | 5.32 B |
| Debt To Equity | 7.03 % | 48.70 % |
| Current Ratio | 0.89 X | 2.16 X |
| Book Value Per Share | (0.01) X | 1.93 K |
| Cash Flow From Operations | (6.95 M) | 971.22 M |
| Earnings Per Share | (0.09) X | 3.12 X |
| Number Of Employees | 4 | 18.84 K |
| Market Capitalization | 4.94 M | 19.03 B |
| Total Asset | 4.01 M | 29.47 B |
| Z Score | 7.2 | 8.72 |
| Net Asset | 4.01 M |
PsyBio Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as PsyBio . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Rate Of Daily Change | 1.0 | |||
| Day Median Price | 1.0E-4 | |||
| Day Typical Price | 1.0E-4 |
About PsyBio Therapeutics Buy or Sell Advice
When is the right time to buy or sell PsyBio Therapeutics Corp? Buying financial instruments such as PsyBio Pink Sheet isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having PsyBio Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Consumption Thematic Idea Now
Consumption
Companies that deliver final goods such as cars or clothing for consumption by consumers. The Consumption theme has 19 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Consumption Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in PsyBio Pink Sheet
PsyBio Therapeutics financial ratios help investors to determine whether PsyBio Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in PsyBio with respect to the benefits of owning PsyBio Therapeutics security.